Corbus Pharmaceuticals Holdings Inc CRBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.68
- Day Range
- $8.87–9.59
- 52-Week Range
- $7.12–20.56
- Bid/Ask
- $8.01 / $9.87
- Shares Outstanding
- 18.53M
- Market Cap
- $167.49M
- Volume/Avg
- 362,835 / 496,175
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 36
- Website
- https://www.corbuspharma.com
Valuation
|
Metric
|
CRBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRBP
|
|---|---|
Quick Ratio | 7.62 |
Current Ratio | 7.92 |
Interest Coverage | — |
Quick Ratio
CRBP
Profitability
|
Metric
|
CRBP
|
|---|---|
Return on Assets (Normalized) | −56.78% |
Return on Equity (Normalized) | −64.59% |
Return on Invested Capital (Normalized) | −67.79% |
Return on Assets
CRBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!zRW?% | LOCK|qf$f | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V&Qj>M! | LOCK|WP<#@ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|kP?SCkL | LOCK|$F | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gv>>KQy | LOCK|j>$F | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<VxfCb | LOCK|%!! | $36B | |||
| Moderna Inc
MRNA
| LOCK|gZrr$wC | LOCK|L% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$<nl>?B | LOCK|MQ<@z | $25B | |||
| Incyte Corp
INCY
| LOCK|tf>d!qw | LOCK|^N | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|yF$^c? | LOCK|tX | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&#p?rCR | LOCK|<rf | $16B |
United States